Nimesh Shah is a Managing Director in the Life Sciences Group. Mr. Shah brings to Hercules over 20 years of venture capital, Wall Street, and operating experience, with an emphasis on working with growth-oriented life science companies.
Prior to joining Hercules in 2018, Mr. Shah served as Chief Business Officer of Fractyl Labs, a clinical-stage company developing innovative technologies to address metabolic disease. Previously, Mr. Shah was a partner of Domain Associates, a leading health-care venture capital firm, and led that firm’s efforts in medical devices. During his time at Domain, Mr. Shah was involved with and served on the boards of a number of portfolio companies, including Twelve (acquired), Sequent Medical (acquired), Fractyl Labs, Zyga Technology (acquired), and Miramar Labs (acquired). Mr. Shah has also served in various roles at venture firm Cutlass Capital and investment bank Alex. Brown (now Deutsche Bank).
Mr. Shah received his Bachelor of Science in Biomedical Engineering from the Johns Hopkins University.